Literature DB >> 21568966

Open label trial to evaluate the efficacy and safety of Yokukansan, a traditional Asian medicine, in dementia with Lewy bodies.

Koh Iwasaki, Kenji Kosaka, Hideo Mori, Reina Okitsu, Katsutoshi Furukawa, Yuta Manabe, Mitsuhiro Yoshita, Aya Kanamori, Nobuo Ito, Kenji Wada, Michio Kitayama, Jun Horiguchi, Shuhei Yamaguchi, Ryuji Fukuhara, Shinji Ouma, Seigo Nakano, Mamoru Hashimoto, Toru Kinoshita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21568966     DOI： 10.1111/j.1532-5415.2011.03373.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  9 in total

1.  Severe metabolic alkalosis, hypokalemia, and respiratory acidosis induced by the Chinese herbal medicine yokukansan in an elderly patient with muscle weakness and drowsiness.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Yasuo Kansui; Yoshinobu Wakisaka; Yuji Uchizono; Kazuhiko Tsuruya; Hiroaki Ooboshi
Journal:  CEN Case Rep       Date:  2012-09-12

2.  Neuroprotective effect of (-)-epigallocatechin-3-gallate on autoimmune thyroiditis in a rat model by an anti-inflammation effect, anti-apoptosis and inhibition of TRAIL signaling pathway.

Authors:  Junfeng Li
Journal:  Exp Ther Med       Date:  2017-11-14       Impact factor: 2.447

3.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 4.  Outcome Measures for Dementia With Lewy Body Clinical Trials: A Review.

Authors:  Bhavana Patel; David J Irwin; Daniel Kaufer; Bradley F Boeve; Angela Taylor; Melissa J Armstrong
Journal:  Alzheimer Dis Assoc Disord       Date:  2022 Jan-Mar 01       Impact factor: 2.357

5.  An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease.

Authors:  Taku Hatano; Nobutaka Hattori; Tadaaki Kawanabe; Yasuo Terayama; Norihiro Suzuki; Yasuo Iwasaki; Toshiki Fujioka
Journal:  J Neural Transm (Vienna)       Date:  2013-10-30       Impact factor: 3.575

6.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Thoyama; Kenta Murotani; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shuichi Ueno; Sachiko Ezoe; Syuzo Hoshino; Haruo Seno
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-14       Impact factor: 2.629

7.  Treatment of posttraumatic stress disorder using the traditional Japanese herbal medicine saikokeishikankyoto: a randomized, observer-blinded, controlled trial in survivors of the great East Japan earthquake and tsunami.

Authors:  Takehiro Numata; Shen Gunfan; Shin Takayama; Satomi Takahashi; Yasutake Monma; Soichiro Kaneko; Hitoshi Kuroda; Junichi Tanaka; Seiki Kanemura; Masayuki Nara; Yutaka Kagaya; Tadashi Ishii; Nobuo Yaegashi; Masahiro Kohzuki; Koh Iwasaki
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-24       Impact factor: 2.629

Review 8.  Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

Authors:  Federico Rodriguez-Porcel; Kathryn A Wyman-Chick; Carla Abdelnour Ruiz; Jon B Toledo; Daniel Ferreira; Prabitha Urwyler; Rimona S Weil; Joseph Kane; Andrea Pilotto; Arvid Rongve; Bradley Boeve; John-Paul Taylor; Ian McKeith; Dag Aarsland; Simon J G Lewis
Journal:  Transl Neurodegener       Date:  2022-05-02       Impact factor: 9.883

9.  Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function.

Authors:  Kenji Takeyoshi; Masatake Kurita; Satoshi Nishino; Mika Teranishi; Yukio Numata; Tadahiro Sato; Yoshiro Okubo
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-15       Impact factor: 2.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.